Abstract
Probiotics survive in gastric environment competing with H. pylori. We studied probiotic “multistrain” administration in dyspeptics with H. pylori (placebo-controlled study).
Forty patients with H. pylori (urea breath test – UBT - and IgG) were treated for 10 days with a mixture of 8 species of probiotics. Control group represented by 40 positive subjects received placebo. A second UBT and H. pylori stool antigen (HpSA) detection were performed after 1 month. Patients who remained infected were treated with triple therapy undergoing another UBT after 30 days. A second line therapy was administered in remaining positive patients. Statistics: Fisher’s exact probability and Student’s t tests.
Thirteen out 40 patients using probiotics became negative, while controls remained positive, irrespectively of the initial UBT delta value. No difference in the eradication rates between the two groups was found (68%-71%). After second line therapy two patients remained positive.Thirteen out 40 patients using probiotics became negative, while controls remained positive, irrespectively of the initial UBT delta value. No difference in the eradication rates between the two groups was found (68%-71%). After second line therapy two patients remained positive.
An adequate supplementation with probiotics might eradicate H. pylori.
Keywords: Eradication, first line therapy, H. pylori, lactobacilli, probiotics, second line therapy
Inflammation & Allergy - Drug Targets (Discontinued)
Title:Probiotic Multistrain Treatment May Eradicate Helicobacter pylori from the Stomach of Dyspeptics: A Placebo-Controlled Pilot Study
Volume: 11 Issue: 3
Author(s): Rosa Rosania, Maria Filomena Minenna, Floriana Giorgio, Antonio Facciorusso, Vincenzo De Francesco, Cesare Hassan, Carmine Panella and Enzo Ierardi
Affiliation:
Keywords: Eradication, first line therapy, H. pylori, lactobacilli, probiotics, second line therapy
Abstract: Probiotics survive in gastric environment competing with H. pylori. We studied probiotic “multistrain” administration in dyspeptics with H. pylori (placebo-controlled study).
Forty patients with H. pylori (urea breath test – UBT - and IgG) were treated for 10 days with a mixture of 8 species of probiotics. Control group represented by 40 positive subjects received placebo. A second UBT and H. pylori stool antigen (HpSA) detection were performed after 1 month. Patients who remained infected were treated with triple therapy undergoing another UBT after 30 days. A second line therapy was administered in remaining positive patients. Statistics: Fisher’s exact probability and Student’s t tests.
Thirteen out 40 patients using probiotics became negative, while controls remained positive, irrespectively of the initial UBT delta value. No difference in the eradication rates between the two groups was found (68%-71%). After second line therapy two patients remained positive.Thirteen out 40 patients using probiotics became negative, while controls remained positive, irrespectively of the initial UBT delta value. No difference in the eradication rates between the two groups was found (68%-71%). After second line therapy two patients remained positive.
An adequate supplementation with probiotics might eradicate H. pylori.
Export Options
About this article
Cite this article as:
Rosania Rosa, Filomena Minenna Maria, Giorgio Floriana, Facciorusso Antonio, De Francesco Vincenzo, Hassan Cesare, Panella Carmine and Ierardi Enzo, Probiotic Multistrain Treatment May Eradicate Helicobacter pylori from the Stomach of Dyspeptics: A Placebo-Controlled Pilot Study, Inflammation & Allergy - Drug Targets (Discontinued) 2012; 11 (3) . https://dx.doi.org/10.2174/187152812800392698
DOI https://dx.doi.org/10.2174/187152812800392698 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets CARD Proteins as Therapeutic Targets in Cancer
Current Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Mucoadhesive Polymeric Platform for Drug Delivery; A Comprehensive Review
Current Drug Delivery The Prognosis of Patients with Liver Metastases from Colorectal Cancer still Depends on Anatomical Presentation more than on Treatments
Current Cancer Drug Targets Advances in the Knowledge and Clinical Applications of Lactic Acid Bacteria as Probiotics in the Urogenital Tract
Current Women`s Health Reviews Natural Radioprotective Agents: An Overview
Current Organic Chemistry Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Current Cancer Drug Targets Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism CuAAC Click Chemistry Accelerates the Discovery of Novel Chemical Scaffolds as Promising Protein Tyrosine Phosphatases Inhibitors
Current Medicinal Chemistry Genetic Polymorphisms in UDP-Glucuronosyltransferase 1A6 Are Not Associated with NSAIDs-Related Peptic Ulcer Haemorrhage
Drug Metabolism Letters Regulation of Ingestive Behavior, the Upper Gastrointestinal Motility and Gastric Acid Secretion by Ghrelin in Mammals
Current Nutrition & Food Science Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design